|
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
|
12 January 2022 |
|
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
|
16 December 2021 |
|
Novartis to sell its Roche stake in a bilateral transaction to Roche
|
08 November 2021 |
|
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
|
22 October 2021 |
|
Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
|
20 October 2021 |
|
Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
|
22 September 2021 |
|
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
|
08 September 2021 |
|
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
|
23 June 2021 |
|
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
|
31 May 2021 |
|
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
|
19 May 2021 |